Article
Molecular assays may aid bladder cancer control
Washington-An evolution in the management of bladder cancer, including the use of molecular-based diagnostic testing, may soon make it possible to achieve better outcomes at a lower cost, according to Mark P. Schoenberg, MD. Dr. Schoenberg, associate professor of urology and oncology and director of the bladder cancer research center at the Johns Hopkins School of Medicine in Baltimore, said that a change in some aspects of bladder cancer management is sorely needed.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS
Can ctDNA detect molecular residual disease in NMIBC?
Expert discusses setting realistic expectations for Rezum for BPH
Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response
Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists
Sacral neuromodulation device empowers patients with greater UUI control
Howard Goldman, MD, on his experience with the Glean Urodynamics System
Remaining Unmet Needs in NMIBC: Closing Thoughts From Expert Panel
Urology Crossroads: Looking Ahead in the Era of Immunotherapy for NMIBC
Study: Women with SCI are more likely to use indwelling catheters
Related Content
